Other · developed by Sionna Therapeutics
SION-451 is an oral tablet studied in cystic fibrosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07035990 | Phase 1 | Cystic Fibrosis (CF) | Completed | SION |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Cystic Fibrosis (CF)
Updated Nov 1, 2026. Something wrong or missing? Report it on the SION page.
See SION's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SION catalysts and pipeline →